BioCentury
ARTICLE | Tools & Techniques

Better cancer mice

November 7, 2005 8:00 AM UTC

Aveo Pharmaceuticals Inc. claims to have a technology platform to create mouse models of cancer that have better predictive value than currently available models. Last week, the company closed a deal with Merck & Co. Inc. to use Aveo's technology to identify genetic profiles correlating with drug response.

As an alternative to xenograft models, in which a human tumor is implanted in an animal, Aveo (Cambridge, Mass.) has developed in vivo inducible mouse tumor models, combining a tissue-specific inducible oncogene with a tumor gene knockout...